The Savannah G2 Atomic Layer Deposition (ALD) System Includes a Complete Suite of Options that Enable the deposition of State-of-the-art Films, and the use of In-situ Analysis for R&D Environments
SAN JOSE, Calif.
- Net income from continuing operations for the first quarter of fiscal 2015 was $13.2 million, or $0.45 per diluted share, compared with $12.4 million, or $0.43 per diluted share, in the fiscal 2014 first quarter
- Adjusted net income from continuing operations for the first quarter of fiscal 2015, excluding certain items, was $18.5 million, or $0.63 per diluted share, a 10.5% improvement over the prior year - Company reaffirms its fiscal 2015 adjusted net income guidance of $2.60 to $2.65 per diluted share AKRON, Ohio , Jan.
"The current momentum behind DOCSIS 3.0 continued again in 3Q14 and shows no signs of stopping," says Jeff Heynen, principal analyst for broadband access at Infonetics Research.
AUSTIN, TX--(Marketwired - January 06, 2015) - Textron Systems Advanced Information Solutions , a Textron Inc. (NYSE: TXT) business, announced today that it has entered into a two-year Cooperative Research and Development Agreement (CRADA) with the U.S. Army Communications-Electronics Research, Development and Engineering Center (CERDEC).
Textron Systems will work with CERDEC's Intelligence Enterprise Branch of Information & Intelligence Warfare Directorate (I2WD) to enhance multi-intelligence collaboration for Warfighter Relevant Cloud Technologies, to be aligned with usability enhancements within the current Distributed Common Ground System - Army (DCGS-A) baseline.
AIRPORT CITY BUSINESS PARK, ISRAEL --
Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™,
today announced that Clinical
Cancer Research published a manuscript describing preclinical
data demonstrating that CRLX101, Cerulean’s proprietary investigational
drug, has potent anti-tumor activity alone and in combination with
Avastin® (bevacizumab) in advanced metastatic ovarian cancer.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.